Why Propanc Biopharma, Inc.’s (PPCB) Stock Is Down 10.30%
As of Friday, August 22, Propanc Biopharma, Inc.’s PPCB share price has dipped by 10.30%, which has investors questioning if this is right time to buy.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Commentary & Analysis
Why Propanc Biopharma, Inc.’s (PPCB) Stock Is Down 10.23%
As of Thursday, August 21, Propanc Biopharma, Inc.’s PPCB share price has dipped by 10.23%, which has investors questioning if this is right time to buy.Omar Beirat
Why Propanc Biopharma, Inc.’s (PPCB) Stock Is Down 30.26%
As of Tuesday, August 19, Propanc Biopharma, Inc.’s PPCB share price has dipped by 30.26%, which has investors questioning if this is right time to buy.Omar Beirat
Is Propanc Biopharma Inc (PPCB) Stock a Good Investment?
Learn more about Propanc Biopharma Inc's (PPCB) stock grades for Momentum and Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.3 | $288.9 | 1% |
|
| Shares Out (Mil) | 0.9 | 54.0 | 4% |
|
| Institutional Ownership | 6.3% | 93.1% | 5% |
|
| Float (Mil) | 1.3 | 41.4 | 3% |
|
| Beta | 3.31 | 0.94 | 98% |
|
| Avg Daily Volume (000s) | 10,333 | 480 | 97% |
|
| Price Change (52-week) |
(98.5%) | 59.9% | 1% |
|
| Growth | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (65.8%) | (10.1%) | 4% |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($43) | 24% |
|
| EPS (TTM) | ($32.408) | ($1.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($31) | 26% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $5 | $190 | 5% |
|
| Valuation | PPCB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.09 | 2.84 | 1% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (99.6%) | (47.7%) | 6% |
|
| ROE | (131.5%) | (55.0%) | 7% |
|
| Liabilities to Assets | 24.5% | 29.6% | 17% |
|
| F-Score | 4 | 3 | na |
|
Propanc Biopharma, Inc. did not pass any screens on 9/2/2026.
